Creation of Value within 2 years through a platform technology for FIVE assets being proprietary cell lines for drug delivery, worth 130 million euro upfront payment/revenue at 3 years.
Multiple partnership opportunities at 3 years following initial investment through out-licensing that bring subsequent milestones payment/revenue.
Re-invent blood transfusion with ready-to-use, off-the-shelf enhanced red blood cells, doing more than simply carry Oxygen as cargo.
